Neuland Laboratories — 360° view

Neuland Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹450 crore and net profit of ₹52 crore for the September 2026 quarter.

Neuland Laboratories (NSE: NEULANDLAB) closed at ₹20,642.00 on 20 Nov 2026, up 23.5% over the past year. Its market capitalisation is ₹26,483 crore and it trades at 58.5 times earnings.

Share price
₹20,642.00 (20 Nov 2026)
Market cap
₹26,483 Cr (20 Nov 2026)
P/E
58.52 (20 Nov 2026)
Revenue
₹450 Cr (September 2026 quarter)
Net profit
₹52 Cr (September 2026 quarter)
ROCE
26.5% (FY26)
ROE
21.2% (FY26)
Book value
₹1,582 (FY26)
Dividend yield
0.16% (last 12 months to 20 Nov 2026)
52-week high / low
₹24,225.00 / ₹11,500.00 (20 Nov 2026)
1-year return
23.5% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: NEULANDLAB

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.